INDIANAPOLIS, Sept. 11, 2017 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) announced that data across its immunology
portfolio will be presented at the annual European Academy of
Dermatology and Venereology Congress (EADV), including Phase 2
safety and efficacy data evaluating Olumiant®
(baricitinib) for the treatment of moderate-to-severe atopic
dermatitis (Lilly and Incyte Corporation are partners on the
development of Olumiant). EADV will take place Sept. 13-17, 2017, in Geneva, Switzerland.
Lilly will also present data for Taltz® (ixekizumab)
from 11 abstracts, including six oral presentations in psoriasis.
Highlighted abstracts include one late-breaker presentation
showcasing Phase 3 data evaluating Taltz for the treatment of
moderate-to-severe genital psoriasis, as well as long-term results
from a five-year, open-label study in moderate-to-severe plaque
psoriasis. Analyses from the IXORA-S study comparing Taltz to
Stelara®* (ustekinumab) and integrated safety and
efficacy results from the SPIRIT-P1 and SPIRIT-P2 studies
evaluating Taltz for the treatment of active psoriatic arthritis
will also be presented.
Two e-posters from the Closer Together Survey, a survey where
1,457 people with moderate-to-severe psoriasis from nine
countries across Europe and
Canada shared how psoriasis
impacts their quality of life and their overall satisfaction with
treatment, will also be presented. An additional four abstracts
will detail results from a selection of studies evaluating the
impact of immune-mediated diseases.
"As a leading forum for dermatologists from around the world, we
are pleased to share a variety of data from across our immunology
portfolio at EADV," said Dr. Lotus Mallbris, vice president,
immunology platform team leader, Lilly Bio-Medicines. "We look
forward to presenting the new clinical and health outcomes results
for Olumiant and Taltz, which reinforce our commitment to advancing
research to address the unmet needs of people living with
dermatologic diseases."
Highlighted presentations and posters include:
Olumiant Data
Oral Presentation
Thursday, Sept. 14
- Abstract FC04.01: 15:00–15:10 CEST, Room F
-
- Baricitinib in Patients with Moderate-to-Severe Atopic
Dermatitis: A Phase 2 Parallel, Double-Blinded, Randomized
Placebo-Controlled Multiple Dose Study
- Presenter: Emma Guttman-Yassky,
M.D., Ph.D., Icahn School of Medicine, Mount Sinai Medical Center,
New York, New York, United States
Taltz Data
Oral Presentations
Thursday, Sept. 14
- Abstract FC02.06: 10:35–10:45 CEST, Room F
-
- Efficacy of Ixekizumab in Patients Previously Treated with
IL-17 Inhibitors
- Presenter: Kim Papp, M.D.,
Ph.D., Probity Medical Research, Waterloo, Ontario, Canada
- Abstract OP01.01: 10:50–11:00 CEST, Room Q
-
- Efficacy, Health-Related Outcomes, and Safety of Ixekizumab for
up to Five Years of Open-Label Treatment in a Phase 2 Study in
Chronic Plaque Psoriasis
- Presenter: Andrew Blauvelt,
M.D., M.B.A., Oregon Medical Research Center, Portland, Oregon, United States
- Abstract FC04.04: 15:30–15:40 CEST, Room F
-
- Further Analysis of Initial Non-Responders to Ixekizumab
Regarding Patient Characteristics and Long-Term Outcomes
- Presenter: Lajos Kemény, M.D., D.Sc., University of Szeged,
Szeged, Hungary
Friday, Sept. 15
- Abstract P03.01: 10:50–11:00 CEST, Room Q
-
- Comparison of Ixekizumab and Ustekinumab Efficacy in the
Treatment of Nail Lesions of Patients with Moderate-to-Severe
Plaque Psoriasis: 24-Week Data from the IXORA-S Trial
- Presenter: Yves Dutronc, M.D., Eli Lilly and Company,
Indianapolis, Indiana,
United States
- Abstract OP04.03: 13:35–13:45 CEST, Room Q
-
- Efficacy and Safety of Continuous Every Two-Week Dosing of
Ixekizumab over 52 Weeks in Patients with Moderate-to-Severe Plaque
Psoriasis
- Presenter: Melinda Gooderham,
M.D., SKiN Centre for Dermatology, Peterborough, Ontario, Canada
Saturday, Sept. 16
- Abstract D3T01.1F: 9:15-9:30
CEST, Room 1
-
- Efficacy and Safety of Ixekizumab in a Randomized,
Double-Blinded, Placebo-Controlled Phase 3b Clinical Trial in
Patients with Moderate-to-Severe Genital Psoriasis
- Presenter: Caitriona Ryan, M.D.,
Consultant Dermatologist, St. Vincent's Hospital, Dublin, Ireland
e-Posters
- Abstract P0389: Integrated Efficacy and Safety Results from
SPIRIT-P1 and SPIRIT-P2, Two Phase 3 Trials of Ixekizumab for the
Treatment of Psoriatic Arthritis
- Abstract P1311: Safety and Tolerability of Ixekizumab:
Integrated Analysis of Safety in Patients with Moderate-to-Severe
Psoriasis from 11 Clinical Trials with more than 12,000
Patient-Years of Exposure to Ixekizumab
- Abstract P1765: Essential Information for Estimating Total
Psoriasis Area and Severity Index (PASI): A Model Developed from a
Post-hoc Analysis of Phase 3 Trials with Ixekizumab and its
Potential Application in Teledermatology
- Abstract P1928: Comparison of Ixekizumab and Ustekinumab in the
Treatment of Scalp Psoriasis in Patients with Moderate-to-Severe
Psoriasis: 24-Week Data from the IXORA-S Trial
- Abstract P1938: A 24-Week, Randomized, Open-Label Comparison of
Ixekizumab Versus Fumaric Acid Esters and Methotrexate in Patients
with Moderate-to-Severe Plaque Psoriasis Naïve to Systemic
Therapy
Additional Data
Oral Presentations
Thursday, Sept. 14
- Abstract FC02.03: 10:05–10:15 CEST, Room F
-
- Patient Perspectives on Symptoms of Genital vs. Non-Genital
Psoriasis: A Qualitative Study
- Presenter: Kim Meeuwis, M.D.,
Radboud University Medical Center, Nijmegen, Netherlands
- Abstract FC02.09: 11:05–11:15 CEST, Room F
-
- How Do Current Treatments for Psoriasis Differ in Terms of
Reaching Low Levels of Absolute Psoriasis Area and Severity Index
(PASI)? Results of a Network Meta-Analysis
- Presenter: Ulrich Mrowietz,
M.D., University Medical Center Schleswig-Holstein, Kiel,
Germany
e-Posters
- Abstract P1024: Association between Duration of Psoriatic Skin
Disease and Subsequent Onset of Psoriatic Arthritis
- Abstract P1799: Content Validity Assessment of the Psoriasis
Symptom Scale for Use in Patients with Moderate-to-Severe
Psoriasis
- Abstract P1998: The Impact of Life Factors on Patients Living
with Psoriasis: An International, Quantitative Survey
- Abstract P1999: Impact of Treatment Goals on Patient
Satisfaction with Treatment of Moderate-to-Severe Psoriasis:
Results from an International Quantitative Survey
INDICATIONS AND USAGE FOR OLUMIANT
Therapeutic
Indications
Baricitinib was approved in February 2017 for the treatment of adults with
moderate-to-severe-active rheumatoid arthritis in the European
Union and is marketed as Olumiant
IMPORTANT SAFETY INFORMATION FOR OLUMIANT BASED ON THE EU
APPROVED SUMMARY OF PRODUCT CHARACTERISTICS
CONTRAINDICATIONS
Hypersensitivity to the active
substance or to any of the excipients.
Pregnancy.
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Infections
Baricitinib is associated with an
increased rate of infections such as upper respiratory tract
infections compared to placebo. In treatment naïve patients,
combination with methotrexate resulted in increased frequency of
infections compared to baricitinib monotherapy. The risks and
benefits of treatment with Olumiant should be carefully considered
prior to initiating therapy in patients with active, chronic or
recurrent infections. If an infection develops, the patient should
be monitored carefully and Olumiant therapy should be temporarily
interrupted if the patient is not responding to standard therapy.
Olumiant treatment should not be resumed until the infection
resolves.
Tuberculosis
Patients should be screened for
tuberculosis (TB) before starting Olumiant therapy. Olumiant should
not be given to patients with active TB. Anti-TB therapy should be
considered prior to initiation of Olumiant in patients with
previously untreated latent TB.
Haematological Abnormalities
Absolute Neutrophil Count (ANC) < 1 x 109 cells/L,
Absolute Lymphocyte Count (ALC) < 0.5 x 109 cells/L
and haemoglobin < 8 g/dL were reported in less than 1% of
patients in clinical trials. Treatment should not be initiated, or
should be temporarily interrupted, in patients with an ANC < 1 x
109 cells/L, ALC < 0.5 x 109 cells/L or
haemoglobin < 8 g/dL observed during routine patient
management.
The risk of lymphocytosis is increased in elderly patients with
rheumatoid arthritis. Rare cases of lymphoproliferative disorders
have been reported.
Viral Reactivation
Viral reactivation, including
cases of herpes virus reactivation (e.g., herpes zoster, herpes
simplex), were reported in clinical studies. Herpes zoster was
reported more commonly in patients ≥ 65 years of age who had
previously been treated with both biologic and conventional DMARDs.
If a patient develops herpes zoster, Olumiant treatment should be
temporarily interrupted until the episode resolves.
Screening for viral hepatitis should be performed in accordance
with clinical guidelines before starting therapy with Olumiant.
Patients with evidence of active hepatitis B or C infection were
excluded from clinical trials. Patients, who were positive for
hepatitis C antibody but negative for hepatitis C virus RNA, were
allowed to participate. Patients with hepatitis B surface antibody
and hepatitis B core antibody, without hepatitis B surface antigen,
were also allowed to participate; such patients should be monitored
for expression of hepatitis B virus (HBV) DNA. If HBV DNA is
detected, a liver specialist should be consulted to determine if
treatment interruption is warranted.
Vaccination
No data are available on the response to
vaccination with live or inactivated vaccines in patients receiving
baricitinib. Use with live, attenuated vaccines during, or
immediately prior to, Olumiant therapy is not recommended.
International treatment guidelines on vaccination in rheumatoid
arthritis patients should be followed when varicella zoster
vaccination is considered prior to treatment with Olumiant.
Lipids
Dose dependent increases in blood lipid
parameters were reported in patients treated with baricitinib
compared to placebo. Elevations in LDL cholesterol decreased to
pre-treatment levels in response to statin therapy. Lipid
parameters should be assessed approximately 12 weeks following
initiation of Olumiant therapy and thereafter patients should be
managed according to international clinical guidelines for
hyperlipidaemia. The effect of these lipid parameter elevations on
cardiovascular morbidity and mortality has not been determined.
Hepatic transaminase elevations
Increases in alanine
transaminase (ALT) and aspartate transaminase (AST) to ≥ 5 and ≥ 10
x upper limit of normal (ULN) were reported in less than 1% of
patients in clinical trials. In treatment-naïve patients,
combination with methotrexate resulted in increased frequency of
hepatic transaminase elevations compared with baricitinib
monotherapy. If increases in ALT or AST are observed during routine
patient management and drug-induced liver injury is suspected,
Olumiant should be temporarily interrupted until this diagnosis is
excluded.
Malignancy
The risk of malignancies including
lymphoma is increased in patients with rheumatoid arthritis.
Immunomodulatory medicinal products may increase the risk of
malignancies including lymphoma. The clinical data are insufficient
to assess the potential incidence of malignancies following
exposure to baricitinib. Long-term safety evaluations are
ongoing.
Venous Thromboembolism
Events of deep venous
thrombosis (DVT) and pulmonary embolism (PE) have been reported in
patients receiving baricitinib. Olumiant should be used with
caution in patients with risk factors for DVT/PE, such as older
age, obesity, a medical history of DVT/PE, or patients undergoing
surgery and immobilisation. If clinical features of DVT/PE occur,
Olumiant treatment should be temporarily interrupted and patients
should be evaluated promptly, followed by appropriate
treatment.
Laboratory Monitoring
Please refer to the SmPC for
laboratory measures and monitoring guidance.
Immunosuppressive Medicinal Products
Combination with biologic DMARDs or other Janus kinase (JAK)
inhibitors is not recommended, as a risk of additive
immunosuppression cannot be excluded. Data concerning use of
baricitinib with potent immunosuppressive medicinal products (e.g.,
azathioprine, tacrolimus, ciclosporin) are limited and caution
should be exercised when using such combinations.
ADVERSE REACTIONS
Undesirable Effects: Summary of
Safety Profile
The most commonly reported adverse drug
reactions (ADRs) occurring in ≥ 2% of patients treated with
Olumiant monotherapy or in combination with conventional synthetic
DMARDs were increased LDL cholesterol (33.6%), upper respiratory
tract infections (14.7%) and nausea (2.8%). Infections reported
with Olumiant treatment included Herpes zoster.
Please see Summary of Product
Characteristics for additional information.
INDICATIONS AND USAGE FOR TALTZ
Taltz® is
indicated for the treatment of adults with moderate-to-severe
plaque psoriasis who are candidates for systemic therapy or
phototherapy.
IMPORTANT SAFETY INFORMATION FOR TALTZ
CONTRAINDICATIONS
Taltz is contraindicated in patients
with a previous serious hypersensitivity reaction, such as
anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Infections
Taltz
may increase the risk of infection. The Taltz group had a higher
rate of infections than the placebo group (27% vs 23%). Serious
infections have occurred. Instruct patients to seek medical advice
if signs or symptoms of clinically important chronic or acute
infection occur. If a serious infection develops, discontinue Taltz
until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate
patients for tuberculosis (TB) infection prior to initiating
treatment with Taltz. Do not administer to patients with active TB
infection. Initiate treatment of latent TB prior to administering
Taltz. Patients receiving Taltz should be monitored closely for
signs and symptoms of active TB during and after treatment.
Hypersensitivity
Serious hypersensitivity reactions,
including angioedema and urticaria (each ≤0.1%), occurred in the
TALTZ group in clinical trials. Anaphylaxis, including cases
leading to hospitalization, has been reported in post-marketing use
with TALTZ. If a serious hypersensitivity reaction occurs,
discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel Disease
Crohn's disease and
ulcerative colitis, including exacerbations, occurred at a greater
frequency in the Taltz group (Crohn's disease 0.1%, ulcerative
colitis 0.2%) than in the placebo group (0%) during clinical
trials. During Taltz treatment, monitor patients for onset or
exacerbations of inflammatory bowel disease.
Immunizations
Prior to initiating therapy with Taltz,
consider completion of all age-appropriate immunizations according
to current immunization guidelines. Live vaccines should not be
given with Taltz.
ADVERSE REACTIONS
Most common adverse reactions
(>1%) associated with Taltz treatment are injection site
reactions, upper respiratory tract infections, nausea, and tinea
infections.
Please see accompanying Prescribing Information
and Medication Guide. Please see
Instructions for Use included with the device.
IX HCP ISI 18JUL2017
*The brand listed is a registered trademark owned or licensed
by Janssen Pharmaceutical Companies of Johnson & Johnson, its
subsidiaries or affiliates, and is not a trademark of Eli Lilly and
Company. The maker of this brand is not affiliated with and does
not endorse Lilly or their products.
About Atopic Dermatitis
Atopic dermatitis (AD), a
serious form of eczema, is a chronic, relapsing skin disease
characterized by intense itching, dry skin and inflammation that
can be present on any part of the body.1 AD is a
heterogeneous disease both clinically and biologically, but may be
characterized by chronic baseline symptoms of itch, redness and
skin damage that are often punctuated with episodic, sometimes
unpredictable, flares or exacerbations.2,3 AD affects
approximately 1-3 percent of adults worldwide.4
Moderate-to-severe AD is characterized by intense itching,
resulting in visibly damaged skin, sleep loss and a significant
impact on patients' quality of life. AD patients often experience
anxiety, depression and reduced self-esteem.5 Like other
chronic inflammatory diseases, AD is immune-mediated and involves a
complex interplay of immune cells and inflammatory
cytokines.6
About Rheumatoid Arthritis
Rheumatoid arthritis (RA)
is an autoimmune disease characterized by inflammation and
progressive destruction of joints. More than 23 million people
worldwide suffer from RA.7 Approximately
three times as many women as men have the
disease.8 Current treatment of RA includes
the use of non-steroidal anti-inflammatory drugs (NSAIDs), oral
conventional disease-modifying antirheumatic drugs (cDMARDs) – such
as methotrexate, the current standard of care, and injectable and
intravenous biological disease-modifying antirheumatic drugs
(bDMARDs) that target selected mediators implicated in the
pathogenesis of RA.9 Despite current
treatment options, many patients do not reach their therapeutic
goals or are not able to achieve sustained
remission.10 There remains an important
need to provide additional treatment options to improve overall
patient care.
About Olumiant®
Olumiant®
(baricitinib) is a once-daily oral JAK inhibitor currently in
clinical studies for inflammatory and autoimmune diseases. There
are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.
JAK-dependent cytokines have been implicated in the pathogenesis of
a number of inflammatory and autoimmune diseases, suggesting that
JAK inhibitors may be useful for the treatment of a broad range of
inflammatory conditions, including rheumatoid arthritis.
In December 2009, Lilly and Incyte
announced an exclusive worldwide license and collaboration
agreement for the development and commercialization of baricitinib
and certain follow-on compounds for patients with inflammatory and
autoimmune diseases. Baricitinib was submitted for regulatory
review seeking marketing approval for the treatment of rheumatoid
arthritis in the U.S., the European Union and Japan in 2016. Baricitinib was approved in the
EU in February 2017 and in
Japan in July 2017. In April
2017, the U.S. Food and Drug Administration issued a
Complete Response Letter on the New Drug Application for
baricitinib. Baricitinib remains under review in other markets. It
is also being studied for the treatment of atopic dermatitis and
systemic lupus erythematosus. The Phase 3 program for psoriatic
arthritis is expected to begin in 2018.
About Moderate-to-Severe Plaque Psoriasis
Psoriasis is
a chronic, immune disease that affects the
skin.11 It occurs when the immune system
sends out faulty signals that speed up the growth cycle of skin
cells. Psoriasis affects approximately 125 million people
worldwide, approximately 20 percent of whom have moderate-to-severe
plaque psoriasis.11,12
Psoriasis can occur on any part of the body and is associated with
other serious health conditions, such as diabetes and heart
disease.11 The most
common form of psoriasis, plaque psoriasis, appears as raised, red
patches covered with a silvery white buildup of dead skin
cells.11
About Active Psoriatic Arthritis
Psoriatic arthritis
(PsA) is a chronic, progressive form of inflammatory arthritis that
can cause swelling, stiffness and pain in and around the joints,
nail changes and impaired physical
function.13 It occurs when an overactive
immune system sends out faulty signals that cause inflammation,
leading to swollen and painful joints and
tendons.14 Typically, psoriatic
arthritis affects peripheral joints in the arms and legs (elbows,
wrists, hands and feet), but can also affect joints in the axial
skeleton (spine, hips and shoulders).15 If
left untreated, PsA can cause permanent joint damage.14 Additionally, up to 30 percent of
people with psoriasis also develop PsA.14
About Taltz®
Taltz® (ixekizumab)
is a monoclonal antibody that selectively binds with interleukin
17A (IL-17A) cytokine and inhibits its interaction with the IL-17
receptor. IL-17A is a naturally occurring cytokine that is involved
in normal inflammatory and immune responses. Taltz inhibits the
release of pro-inflammatory cytokines and chemokines.
Lilly has filed a supplemental Biologics License Application
(sBLA) with the U.S. Food and Drug Administration (FDA) for Taltz
for the treatment of active PsA. Lilly also submitted Taltz to the
European Medicines Agency (EMA) for the treatment of adult patients
with active PsA. Taltz is approved for adult patients with active
PsA in Japan. Submissions to other
regulatory agencies around the world are expected later this year.
Taltz is also in Phase 3 trials for the treatment of radiographic
and non-radiographic axial spondyloarthritis.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on the discovery, development and commercialization
of proprietary therapeutics. For additional information on Incyte,
please visit the Company's web site at www.incyte.com.
Follow @Incyte on Twitter
at https://twitter.com/Incyte.
P-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about Taltz (ixekizumab) as a treatment for
moderate-to-severe plaque psoriasis, and reflects Lilly's current
belief. This press release also contains forward-looking statements
(as that term is defined in the Private Securities Litigation
Reform Act of 1995) about baricitinib as a potential treatment for
patients with rheumatoid arthritis, and reflects Lilly's
and Incyte's current belief. As with any pharmaceutical
product, there are substantial risks and uncertainties in the
process of development and commercialization. Among other things,
there can be no guarantee that future study results will be
consistent with the results to date, that Taltz or baricitinib will
receive additional regulatory approvals, or be commercially
successful. For further discussion of these and other risks and
uncertainties, see Lilly's and Incyte's most recent Form
10-K and Form 10-Q filings with the United States Securities
and Exchange Commission. Except as required by law, Lilly
and Incyte undertake no duty to update forward-looking
statements to reflect events after the date of this release.
1 Zuberbier T, Orlow SJ, Paller AS, et al. Patient
perspectives on the management of atopic dermatitis. The Journal
of Allergy and Clinical Immunology. 2006;118: 226-32.
2 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al.
Moving toward endotypes in atopic dermatitis: identification of
patient clusters based on serum biomarker analysis. The Journal
of Allergy and Clinical Immunology. 2017.
3 Langan SM, Thomas KS,
Williams HC. What is meant by "flare" in atopic dermatitis? A
systematic review and proposal. Arch Dermatol.
2006;142:1190-1196.
4 Nutten S. Atopic dermatitis: global epidemiology and
risk factors. Annals of Nutrition and Metabolism.
2015;66(suppl 1): 8-16.
5 Yosipovitch G, Papoiu AD. What causes itch in atopic
dermatitis? Current Allergy and Asthma Reports.
2008;8:306-311.
6 Weidinger, S, Novak, N. Atopic dermatitis. The
Lancet Volume 387. 2016;10023:1109-1122.
7 WHO Global Burden of Disease Report, (table 7, page
32) 2004,
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
Accessed August 30, 2017.
8 Arthritis Foundation, What is Rheumatoid Arthritis?,
http://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/what-is-rheumatoid-arthritis.php.
Accessed September 8, 2017.
9 Arthritis Foundation, Rheumatoid Arthritis Treatment,
http://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/treatment.php.
Accessed September 8, 2017.
10 McWilliams DF, Kiely PDW, Young A, Walsh DA. Baseline
factors predicting change from the initial DMARD treatment during
the first 2 years of rheumatoid arthritis: experience in the ERAN
inception cohort. BMC Musculoskeletal Disorders. 2013;14:1-7.
11 Psoriasis media kit. National Psoriasis Foundation
website.
https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf.
Accessed September 8, 2017.
12 Psoriasis. American Academy of Dermatology website.
https://www.aad.org/media-resources/stats-and-facts/conditions/psoriasis.
Accessed September 8, 2017.
13 About psoriatic arthritis. National Psoriasis
Foundation website.
https://www.psoriasis.org/about-psoriatic-arthritis. Accessed
September 8, 2017.
14 What is psoriatic arthritis? Arthritis Foundation
website.
http://www.arthritis.org/about-arthritis/types/psoriatic-arthritis/what-is-psoriatic-arthritis.php.
Accessed September 8, 2017.
15 Classification of psoriatic arthritis. National
Psoriasis Foundation website.
https://www.psoriasis.org/psoriatic-arthritis/classification-of-psoriatic-arthritis.
Accessed September 8, 2017.
Refer to:
|
Danielle Neveles;
danielle.neveles@lilly.com; +1-317-796-4564 (Lilly
media)
|
|
Phil Johnson;
johnson_philip_l@lilly.com; +1-317-655-6874 (Lilly
investors)
|
|
Catalina Loveman;
cloveman@incyte.com; +1-302-498-6171 (Incyte media)
|
|
Michael Booth, DPhil;
mbooth@incyte.com; +1-302-498-5914 (Incyte investors)
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-to-present-new-data-for-olumiant-baricitinib-and-taltz-ixekizumab-at-the-european-academy-of-dermatology-and-venereology-eadv-annual-congress-300516850.html
SOURCE Eli Lilly and Company